查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806204

再生醫學市場（按產品類型、來源、應用領域和最終用戶）—2025-2030 年全球預測

Regenerative Medicine Market by Product Type, Source, Application Areas, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

再生醫學市場預計到 2024 年將達到 283.5 億美元，2025 年將達到 349.9 億美元，到 2030 年將達到 1,024 億美元，複合年成長率為 23.86%。

主要市場統計數據
基準年2024年 283.5億美元
預計2025年 349.9億美元
預測年份 2030 1024億美元
複合年成長率（%） 23.86%

探索再生醫學作為現代醫療創新和治療發展的變革前沿的不斷發展的前景

再生醫學正處於模式轉移的風口浪尖，這將重新定義治療慢性和退化性疾病的可能性。在細胞生物學、生物材料科學和基因編輯技術的推動下，該領域正從理論可能性走向具體的臨床實踐。從幹細胞療法的開創性努力到基於細胞的精細方法，研究人員和臨床醫生都見證了前所未有的治療潛力。隨著全球醫療生態系統努力應對心血管疾病、神經系統疾病和複雜傷口日益增多的趨勢，再生策略為傳統藥物介入提供了極具吸引力的替代方案。因此，在學術界、產業界和監管機構的協力網路的支持下，研發投入正在激增。

確定推動再生醫學模式轉移的關鍵曲折點，塑造充滿活力的未來治療創新生態系統

再生醫學領域正經歷一系列曲折點，重塑其策略方向。精準基因編輯領域的最新突破促進了治療有效載荷的更高效遞送，彌合了概念研究與可擴展臨床應用之間的差距。同時，人工智慧和機器學習工具的整合正在透過加速標靶發現和最佳化生產流程來縮短開發時間。與這些技術加速器相輔相成的是主要市場的先進法律規範，這些框架正在引入快速核准途徑和自適應許可模式，以更快地滿足未滿足的醫療需求。

評估2025年美國關稅變化對國際再生醫學供應網路和合作研究聯盟的影響

2025年，美國實施了一系列關稅調整，對全球再生醫學供應網路產生了顯著的連鎖反應。儘管其初衷是為了保護國內產能，但對生物原料、病毒載體和專用支架組件的進口關稅上調，卻增加了許多國際合作夥伴的生產成本。因此，製造商和研究機構不得不重新思考籌資策略，探索近岸外包機會和其他區域中心，以緩解不斷上升的成本壓力。

揭示深層市場細分視角，揭示再生醫學產品、供應商、應用和最終用戶的策略路徑

細緻入微地了解市場區隔對於制定策略投資和確定研究路徑的優先順序至關重要。根據產品類型，該領域涵蓋多種模式，從細胞療法到細胞外和細胞培養方法、基因療法解決方案和組織工程平台。在細胞療法中，區分無幹細胞治療方法，例如樹突狀細胞、自然殺手細胞和 T 細胞等免疫細胞產品，以及利用多功能細胞或成體前驅細胞群的基於幹細胞的治療方法。基因編輯技術、基因遞送載體以及基於 RNA 和 DNA 的系統帶來了額外的複雜性，載體分類擴展到非病毒和病毒平台。組織工程進一步細分為生醫材料、生長因子和細胞激素配方以及支架構建體，天然生物材料和合成生醫材料的選擇決定了性能和成本生醫材料的差異。

分析美洲、中東和非洲以及亞太地區再生醫學生態系中塑造機會的區域動態

區域差異在塑造再生醫學領域的投資決策、監管趨勢和商業化策略方面發揮關鍵作用。在美洲，強勁的私人和公共資金籌措正在加速臨床應用，大幅擴大先進製造地，並簡化新治療方法的核准流程。該地區領先的研究機構和行業相關人員之間的跨境合作正在建立卓越中心，並促進最先進治療的快速迭代。

與業界領先的先驅者會面，他們透過策略合作夥伴關係引領再生醫學的商業道路

領先的公司正在透過多元化策略發展其產品組合，以平衡內部研發與外部合作。一些先鋒生物製藥公司正在建立專門的細胞和基因治療部門，以匯集專業知識並加速產品線開發。這些團隊利用內部能力以及與學術中心和專業合約開發公司的策略夥伴關係，獲得靈活性和規模。合資企業也正在成為共同投資製造基礎設施的首選方式，以確保在整個開發過程中利益一致、風險共用。

提供有針對性的建議，使領導者能夠加速創新，推動永續成長，並克服再生醫學領域的關鍵挑戰

為了因應複雜的再生醫學環境，產業領導者應採取涵蓋策略、營運和監管等多方面措施。首先，與學術機構和專業合約組織建立強而有力的夥伴關係關係，可以加速研發管線的進展，同時降低資本支出風險。協調獎勵並共同投資模組化製造平台，可以幫助相關人員在生產需求不斷成長的情況下保持敏捷。

我們嚴謹的調查方法，結合原始資料和二次資料分析，提供全面的再生醫學見解

本報告中提出的見解是基於嚴格的混合方法框架，旨在確保研究的深度和有效性。主要研究包括對一系列相關人員的深入訪談，涵蓋從科學創始人和製程工程師到監管專家和商業策略家的方方面面。這些對話旨在揭示關於技術採用、監管趨勢和臨床開發挑戰的微妙觀點。同時，二次資料分析借鑒了同行評審文獻、政府政策文件和公開的臨床試驗庫，以檢驗新興趨勢和基準。

全球再生醫學動態和市場影響因素綜合研究的關鍵要點和策略重點摘要

再生醫學領域正處於曲折點，其特徵包括技術突破、監管格局的演變以及全球供應網路的策略調整。在支持性政策框架和不斷提升的生產能力的推動下，先進的細胞和基因療法正從實驗階段走向近期的商業化階段。主要市場的關稅調整帶來了成本壓力和供應鏈複雜性，同時也催化了本地生產和建立韌性夥伴關係的創新策略。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 擴大慢性創傷治療的再生療法
  • 基因編輯技術的進步加速創新
  • 產學合作促進再生產品開發
  • 透過人工智慧整合最佳化再生醫學研究
  • 對抗老齡化相關疾病的再生解決方案需求不斷成長
  • 新型生物材料的出現增強了支架在再生的有效性
  • 3D生物列印技術在組織工程的應用日益廣泛
  • 幹細胞療法的進步推動個人化再生治療
  • 監管演變改善再生醫學核准途徑
  • 支持再生醫學Start-Ups企業和臨床試驗的投資激增

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章再生醫學市場（依產品類型）

  • 細胞療法
    • 非幹細胞療法
      • 免疫細胞
      • 樹突狀細胞
      • 自然殺手（NK）細胞
      • T細胞
      • 非免疫細胞
    • 幹細胞療法
  • 細胞外和無細胞療法
  • 基因治療
    • 基因編輯技術
    • 基因轉移載體
      • 非病毒載體
      • 病毒載體
    • 基於RNA和DNA的治療方法
  • 組織工程
    • 生物材料
      • 天然生醫材料
      • 合成生醫材料
    • 生長因子和細胞激素
    • 鷹架

第9章 再生醫學市場（依來源）

  • 同種異體
  • 自體移植
  • 合成
  • 異質

第 10 章 再生醫學市場（按應用）

  • 心血管系統
    • 血管生成和血管重建
    • 先天性心臟疾病修復
    • 心臟瓣膜置換術
    • 心肌梗塞的治療
  • 皮膚科
    • 美容手術
    • 燒燙傷治療
    • 慢性創傷治療
  • 糖尿病
    • BETA細胞移植
    • 胰島細胞再生
  • 神經病學
    • 阿茲海默症治療
    • 多發性硬化症的治療
    • 帕金森氏症的治療
    • 脊髓損傷修復
    • 中風復健
  • 腫瘤學
    • 癌症免疫治療
    • 腫瘤消融
  • 眼科
    • 角膜修復
    • 視網膜再生
  • 整形外科和肌肉骨骼
    • 骨再生
    • 軟骨修復
    • 肌腱修復

第 11 章 再生醫學市場（依最終使用者）

  • 學術研究機構
  • 合約研究組織
  • 醫院和診所
  • 製藥和生物技術公司

第 12 章：美洲再生醫學市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 13 章：歐洲、中東和非洲的再生醫學市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

第 14 章：亞太再生醫學市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • 4D Molecular Therapeutics, Inc.
    • AbbVie Inc.
    • Abeona Therapeutics Inc.
    • Adaptimmune Therapeutics PLC
    • Adverum Biotechnologies, Inc.
    • AGC Biologics
    • Astellas Pharma Inc.
    • Bayer AG
    • CMIC Co., Ltd.
    • CRISPR Therapeutics AG
    • F. Hoffmann-La Roche Ltd.
    • Fate Therapeutics, Inc.
    • FUJIFILM Holdings Corporation
    • Gilead Sciences, Inc.
    • HEALIOS KK
    • Integra LifeSciences Holdings Corporation
    • JCR Pharmaceuticals Co., Ltd.
    • Johnson & Johnson
    • Merck KGaA
    • Mesoblast Limited
    • Novartis AG
    • Orchard Therapeutics PLC
    • Organogenesis Holdings Inc.
    • Pfizer Inc.
    • Pluri Biotech Ltd.
    • Poseida Therapeutics, Inc.
    • REPROCELL Inc.
    • SanBio Company Limited
    • Stryker Corporation
    • Sumitomo Pharma Co., Ltd.
    • Sysmex Corporation
    • Takeda Pharmaceutical Company Limited
    • Tenaya Therapeutics, Inc.
    • Vericel Corporation
    • Voyager Therapeutics Inc.
    • Zimmer Biomet Holdings, Inc.

第16章 研究人工智慧

第17章 研究統計

第18章 研究聯絡人

第19章 研究報導

第20章 附錄

Product Code: MRR-430D42AA0F5B

The Regenerative Medicine Market was valued at USD 28.35 billion in 2024 and is projected to grow to USD 34.99 billion in 2025, with a CAGR of 23.86%, reaching USD 102.40 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 28.35 billion
Estimated Year [2025] USD 34.99 billion
Forecast Year [2030] USD 102.40 billion
CAGR (%) 23.86%

Exploring the Evolutionary Landscape of Regenerative Medicine as a Transformative Frontier in Modern Healthcare Innovation and Therapeutic Development

Regenerative medicine stands at the cusp of a paradigm shift, redefining what is possible in the treatment of chronic and degenerative diseases. Fueled by advances in cell biology, biomaterials science, and gene editing technologies, this discipline is moving beyond theoretical promise into tangible clinical realities. From pioneering trials in stem cell therapies to the refinement of acellular approaches, researchers and clinicians alike are witnessing unprecedented therapeutic potential. As the global healthcare ecosystem grapples with rising incidences of cardiovascular disorders, neurological conditions, and complex wounds, regenerative strategies offer a compelling alternative to traditional pharmacological interventions. Consequently, investment in research and development has surged, supported by collaborative networks spanning academia, industry, and regulatory bodies.

In response to these trends, this executive summary distills the critical developments shaping the regenerative medicine landscape. It highlights key technological breakthroughs, examines the evolving regulatory environment, and explores how shifting reimbursement paradigms are influencing stakeholder decision-making. Moreover, this report delves into supply chain dynamics and policy influences that will dictate future trajectories. By synthesizing qualitative insights from expert interviews with rigorous secondary analysis, the summary offers a comprehensive foundation for strategic planning. Ultimately, this introduction sets the stage for an in-depth examination of transformative shifts, tariff implications, segmentation patterns, regional dynamics, and actionable recommendations essential for leaders seeking to capitalize on the regenerative medicine revolution.

Identifying Critical Inflection Points Driving the Paradigm Shift in Regenerative Therapies and Shaping a Dynamic Future Ecosystem of Treatment Innovation

The regenerative medicine sector is experiencing a series of inflection points that are collectively reshaping its strategic direction. Recent breakthroughs in precision gene editing have facilitated more efficient delivery of therapeutic payloads, bridging the gap between conceptual research and scalable clinical application. At the same time, integration of artificial intelligence and machine learning tools is accelerating target discovery and optimizing manufacturing workflows, thereby reducing development timelines. These technological accelerators are complemented by progressive regulatory frameworks in key markets, which are progressively offering accelerated approval pathways and adaptive licensing models to address unmet medical needs more rapidly.

Simultaneously, growing alignment between biopharmaceutical sponsors and specialized contract development and manufacturing organizations is fostering greater agility and cost-effectiveness within supply chains. This shift reflects a broader ecosystem trend toward modular, flexible manufacturing that can accommodate personalized therapies and small-batch production. In parallel, rising engagement from venture capital and nontraditional investors signals heightened confidence in the commercial viability of regenerative products. As public-private partnerships evolve and philanthropic funding supports early-stage innovation, the sector is transitioning from siloed research efforts into a cohesive network of collaborative ventures. Consequently, stakeholders must navigate an increasingly dynamic environment characterized by cross-disciplinary alliances, regulatory flexibility, and next-generation manufacturing strategies.

Assessing the Impact of United States Tariff Changes in 2025 on International Regenerative Medicine Supply Networks and Collaborative Research Alliances

In 2025, the United States implemented a series of tariff adjustments that have generated substantial ripple effects throughout the global regenerative medicine supply network. While the intention was to protect domestic manufacturing capabilities, increased import duties on raw biomaterials, viral vectors, and specialized scaffolding components have elevated production costs for many international partners. Consequently, manufacturers and research institutions have had to recalibrate sourcing strategies, exploring nearshoring opportunities and alternative regional hubs to mitigate escalating expense pressures.

Moreover, these tariff changes have spurred a strategic realignment of collaborative research alliances. Firms are seeking to establish integrated supply chain partnerships within tariff-friendly jurisdictions, thereby preserving cost efficiencies while maintaining access to critical inputs. Academic and contract organizations have intensified negotiations to secure long-term procurement contracts, often involving co-investment in localized production facilities. Although these measures have introduced temporary delays in certain clinical trial timelines, they have also catalyzed innovative manufacturing approaches, such as single-use bioreactors and modular cleanroom systems, which reduce dependence on cross-border shipments.

Looking ahead, stakeholders must remain vigilant to policy shifts that could further influence trade dynamics. Engaging proactively with regulatory and legislative bodies will be crucial to shaping more balanced tariff frameworks and developing resilient supply networks. In doing so, industry participants can safeguard research continuity, accelerate product development, and foster sustainable growth despite evolving trade policies.

Unveiling Deep Market Segmentation Perspectives to Illuminate Strategic Pathways in Product, Source, Application, and End User Dimensions of Regenerative Medicine

A nuanced understanding of market segmentation is essential for framing strategic investments and prioritizing research pathways. Based on product type, the sector encompasses a diverse array of modalities ranging from cell therapy to extracelluar and acellular approaches, gene therapy solutions, and tissue engineering platforms. Within cell therapy, distinctions emerge between non-stem cell-based modalities-such as immune cell products including dendritic cells, natural killer cells, and T cells-and stem cell-based interventions that leverage pluripotent and adult progenitor populations. Gene editing technologies, gene transfer vectors, and RNA- or DNA-based systems present additional layers of complexity, with vector classifications extending to non-viral and viral-based platforms. Tissue engineering further subdivides into biomaterials, growth factor and cytokine formulations, and scaffold constructs, wherein the choice between natural and synthetic biomaterials drives differential performance and cost profiles.

When considering source origin, therapeutic products are categorized as allogeneic, autologous, synthetic, or xenogeneic, each possessing distinct immunological and manufacturing considerations. Application areas span a broad clinical spectrum, including cardiovascular interventions for angiogenesis and valve repair, dermatological treatments for burn wounds and chronic lesions, and diabetes therapeutics focused on beta cell transplantation. Neurology targets encompass Alzheimer's disease, multiple sclerosis, Parkinson's therapeutics, spinal cord repair, and post-stroke recovery, while oncology strategies leverage immunotherapy and ablative modalities. Ophthalmological innovations address corneal and retinal regeneration, and orthopedic and musculoskeletal repairs concentrate on bone, cartilage, and tendon restoration. End users range from academic research centers and contract research organizations to hospitals, clinics, and pharmaceutical and biotechnology enterprises, each bringing unique procurement criteria and adoption timelines to the landscape.

Analyzing Regional Dynamics Shaping Opportunities in the Americas, Europe Middle East Africa, and Asia Pacific Across the Regenerative Medicine Ecosystem

Regional nuances play a pivotal role in shaping investment decisions, regulatory trajectories, and commercialization strategies across the regenerative medicine field. In the Americas, robust funding from private and public sources has accelerated clinical translation, with notable expansion of advanced manufacturing hubs and streamlined approval processes for novel therapies. Cross-border collaborations between leading research institutions and industry participants in this region have established centers of excellence, fostering rapid iteration of cutting-edge treatments.

Transitioning to Europe, the Middle East, and Africa, a mosaic of regulatory frameworks and reimbursement models influences market entry strategies. While some jurisdictions offer adaptive regulatory pathways and research incentives, others maintain more conservative approaches that require comprehensive safety and efficacy data. Consequently, strategic alliances and consortium-based research initiatives are common tools for managing heterogeneous policy landscapes. Emerging markets within this region are increasingly attractive for early-stage trials, owing to evolving infrastructure and competitive cost environments.

Across the Asia Pacific, ambitious government programs and supportive policy initiatives have catalyzed exponential growth in both academic research and commercial manufacturing capacity. Local manufacturers are investing heavily in scalable bioproduction facilities, while multinational companies are engaging in technology transfer agreements to localize supply chains. The convergence of favorable regulatory reforms, growing patient populations, and competitive operational costs has positioned this region as a critical hub for future regenerative medicine innovation.

Highlighting Leading Industry Pioneers Driving Competition through Strategic Alliances That Are Redefining Commercialization Pathways in Regenerative Medicine

Leading organizations are advancing portfolios through diverse strategies that balance internal R&D with external collaborations. Several pioneering biopharma firms have established dedicated cell and gene therapy divisions to consolidate expertise and accelerate pipeline development. These teams leverage in-house capabilities alongside strategic partnerships with academic centers and specialized contract developers to enhance flexibility and scale. Joint ventures are also emerging as a preferred vehicle for co-investing in manufacturing infrastructure, ensuring aligned incentives and shared risk across development timelines.

Furthermore, innovative biotech start-ups are differentiating themselves by targeting niche applications such as neuroregeneration and immuno-oncology, often supported by venture capital and philanthropic grants. These nimble players benefit from agile decision-making processes, allowing them to pivot rapidly based on emerging preclinical and clinical data. Meanwhile, established pharmaceutical companies are incorporating regenerative modalities into existing therapeutic platforms, integrating novel cell or gene therapies with established small molecule or biologic regimens to deliver combination treatments.

Across the ecosystem, intellectual property strategies are evolving to cover not only core therapeutic constructs but also manufacturing processes, delivery devices, and data analytics algorithms. This holistic approach safeguards competitive advantage while enabling cross-licensing arrangements that facilitate market entry. As the competitive landscape intensifies, effective portfolio management and alignment of scientific expertise with operational excellence will remain critical determinants of success.

Delivering Targeted Recommendations to Empower Leaders to Accelerate Innovation, Foster Sustainable Growth and Overcome Key Challenges in Regenerative Medicine

To navigate the complex regenerative medicine environment, industry leaders should adopt a multifaceted approach that spans strategic, operational, and regulatory dimensions. First, forging robust partnerships with academic institutions and specialized contract organizations can accelerate pipeline progression while mitigating capital expenditure risks. By aligning incentives and co-investing in modular manufacturing platforms, stakeholders can maintain agility even as production demands scale.

Second, investing in advanced analytics and digital technologies will be paramount to optimizing clinical trial design and real-time monitoring. Leveraging machine learning for patient stratification and predictive safety assessments can reduce development timelines and enhance trial success rates. Concurrently, establishing robust quality management systems and early engagement with regulatory authorities will streamline approval pathways and support adaptive trial models.

Third, diversifying geographic footprint through the establishment of regional centers of excellence can safeguard against policy volatility and supply chain disruptions. Engaging proactively in policy dialogues and public-private partnerships will help shape balanced regulatory frameworks while unlocking incentives for local production. Lastly, cultivating a holistic intellectual property strategy that encompasses core assets, manufacturing know-how, and data management algorithms will ensure differentiated market positioning. By executing these targeted recommendations, leaders can accelerate innovation, sustain competitive advantage, and deliver transformative therapies to patients worldwide.

Detailing a Rigorous Research Methodology Integrating Primary Interviews with Secondary Data Analysis to Deliver Comprehensive Regenerative Medicine Insights

The insights presented in this report are grounded in a rigorous mixed-methodology framework designed to ensure both depth and validity. Primary research included in-depth interviews with a cross-section of stakeholders, ranging from scientific founders and process engineers to regulatory experts and commercial strategists. These conversations were structured to uncover nuanced perspectives on technology adoption, regulatory trends, and clinical development challenges. In parallel, secondary data analysis leveraged peer-reviewed literature, government policy documents, and publicly disclosed clinical trial repositories to validate emerging trends and benchmarks.

To triangulate findings, an expert validation panel comprising thought leaders from academia, industry associations, and non-profit research organizations reviewed preliminary conclusions. This validation step was integral for refining thematic priorities and verifying the accuracy of market segmentation frameworks. Methodological rigor was further enhanced through consistency checks and cross-regional comparisons, ensuring that insights account for local policy nuances and supply chain dynamics. By integrating qualitative depth with quantitative context, this report delivers a comprehensive and actionable perspective on the global regenerative medicine landscape.

Summarizing Key Takeaways and Strategic Imperatives from the Comprehensive Examination of Regenerative Medicine Dynamics and Market Influencers Worldwide

The regenerative medicine sector is at an inflection point defined by technological breakthroughs, evolving regulatory landscapes, and strategic realignments within global supply networks. Advanced cell and gene therapies are transitioning from experimental stages to near-term commercialization, driven by supportive policy frameworks and expanding manufacturing capabilities. While tariff adjustments in key markets have introduced cost pressures and supply chain complexities, they have also catalyzed innovative strategies for localized production and resilient partnerships.

Segmentation analysis reveals the multiplicity of therapeutic modalities and end-user requirements, underscoring the importance of tailored approaches across product types, sources, application areas, and organizational buyers. Regional insights highlight the Americas, Europe Middle East Africa, and Asia Pacific as critical ecosystems, each offering unique advantages in terms of funding, regulatory agility, and infrastructure. Competitive dynamics continue to be shaped by strategic alliances, intellectual property portfolios, and investments in digital platforms for clinical and manufacturing optimization.

Looking forward, stakeholders must embrace collaborative innovation models, proactive policy engagement, and adaptive commercialization strategies to capitalize on the full potential of regenerative medicine. By synthesizing these key takeaways and imperatives, industry participants can better position themselves to deliver transformative therapies, drive sustainable growth, and ultimately improve patient outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of regenerative therapies targeting chronic wound healing
  • 5.2. Growth of gene editing techniques accelerating regenerative medicine innovation
  • 5.3. Collaborations between academia and industry fueling regenerative product development
  • 5.4. Integration of artificial intelligence to optimize regenerative medicine research
  • 5.5. Rising demand for regenerative solutions addressing age-related disorders
  • 5.6. Emergence of novel biomaterials enhancing scaffold effectiveness in regeneration
  • 5.7. Increasing adoption of 3D bioprinting technology in tissue engineering
  • 5.8. Advancements in stem cell therapies driving personalized regenerative treatments
  • 5.9. Regulatory evolution improving approval pathways for regenerative treatments
  • 5.10. Surge in investments supporting regenerative medicine startups and clinical trials

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Regenerative Medicine Market, by Product Type

  • 8.1. Introduction
  • 8.2. Cell Therapy
    • 8.2.1. Non-Stem Cell-Based Therapy
      • 8.2.1.1. Immune Cells
      • 8.2.1.1.1. Dendritic Cells
      • 8.2.1.1.2. Natural Killer (NK) Cells
      • 8.2.1.1.3. T Cells
      • 8.2.1.2. Non-immune Cells
    • 8.2.2. Stem Cell-Based Therapy
  • 8.3. Extracellular & Acellular Therapies
  • 8.4. Gene Therapy
    • 8.4.1. Gene Editing Technologies
    • 8.4.2. Gene Transfer Vectors
      • 8.4.2.1. Non-Viral Vectors
      • 8.4.2.2. Viral Vectors
    • 8.4.3. RNA & DNA-Based Therapies
  • 8.5. Tissue Engineering
    • 8.5.1. Biomaterials
      • 8.5.1.1. Natural Biomaterials
      • 8.5.1.2. Synthetic Biomaterials
    • 8.5.2. Growth Factors & Cytokines
    • 8.5.3. Scaffolds

9. Regenerative Medicine Market, by Source

  • 9.1. Introduction
  • 9.2. Allogeneic
  • 9.3. Autologous
  • 9.4. Synthetic
  • 9.5. Xenogeneic

10. Regenerative Medicine Market, by Application Areas

  • 10.1. Introduction
  • 10.2. Cardiovascular
    • 10.2.1. Angiogenesis & Vascular Regeneration
    • 10.2.2. Congenital Heart Defect Repair
    • 10.2.3. Heart Valve Replacement
    • 10.2.4. Myocardial Infarction Treatment
  • 10.3. Dermatology
    • 10.3.1. Aesthetic Procedures
    • 10.3.2. Burn Treatment
    • 10.3.3. Chronic Wound Healing
  • 10.4. Diabetes
    • 10.4.1. Beta Cell Transplantation
    • 10.4.2. Islet Cell Regeneration
  • 10.5. Neurology
    • 10.5.1. Alzheimer's Treatment
    • 10.5.2. Multiple Sclerosis Therapy
    • 10.5.3. Parkinson's Therapy
    • 10.5.4. Spinal Cord Injury Repair
    • 10.5.5. Stroke Recovery
  • 10.6. Oncology
    • 10.6.1. Cancer Immunotherapy
    • 10.6.2. Tumor Ablation
  • 10.7. Ophthalmology
    • 10.7.1. Corneal Repair
    • 10.7.2. Retinal Regeneration
  • 10.8. Orthopedic & Musculoskeletal
    • 10.8.1. Bone Regeneration
    • 10.8.2. Cartilage Repair
    • 10.8.3. Tendon Repair

11. Regenerative Medicine Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutes
  • 11.3. Contract Research Organizations
  • 11.4. Hospitals & Clinics
  • 11.5. Pharmaceutical & Biotechnology Companies

12. Americas Regenerative Medicine Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Regenerative Medicine Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Regenerative Medicine Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. 4D Molecular Therapeutics, Inc.
    • 15.3.2. AbbVie Inc.
    • 15.3.3. Abeona Therapeutics Inc.
    • 15.3.4. Adaptimmune Therapeutics PLC
    • 15.3.5. Adverum Biotechnologies, Inc.
    • 15.3.6. AGC Biologics
    • 15.3.7. Astellas Pharma Inc.
    • 15.3.8. Bayer AG
    • 15.3.9. CMIC Co., Ltd.
    • 15.3.10. CRISPR Therapeutics AG
    • 15.3.11. F. Hoffmann-La Roche Ltd.
    • 15.3.12. Fate Therapeutics, Inc.
    • 15.3.13. FUJIFILM Holdings Corporation
    • 15.3.14. Gilead Sciences, Inc.
    • 15.3.15. HEALIOS K.K.
    • 15.3.16. Integra LifeSciences Holdings Corporation
    • 15.3.17. JCR Pharmaceuticals Co., Ltd.
    • 15.3.18. Johnson & Johnson
    • 15.3.19. Merck KGaA
    • 15.3.20. Mesoblast Limited
    • 15.3.21. Novartis AG
    • 15.3.22. Orchard Therapeutics PLC
    • 15.3.23. Organogenesis Holdings Inc.
    • 15.3.24. Pfizer Inc.
    • 15.3.25. Pluri Biotech Ltd.
    • 15.3.26. Poseida Therapeutics, Inc.
    • 15.3.27. REPROCELL Inc.
    • 15.3.28. SanBio Company Limited
    • 15.3.29. Stryker Corporation
    • 15.3.30. Sumitomo Pharma Co., Ltd.
    • 15.3.31. Sysmex Corporation
    • 15.3.32. Takeda Pharmaceutical Company Limited
    • 15.3.33. Tenaya Therapeutics, Inc.
    • 15.3.34. Vericel Corporation
    • 15.3.35. Voyager Therapeutics Inc.
    • 15.3.36. Zimmer Biomet Holdings, Inc.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. REGENERATIVE MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. REGENERATIVE MEDICINE MARKET: RESEARCHAI
  • FIGURE 24. REGENERATIVE MEDICINE MARKET: RESEARCHSTATISTICS
  • FIGURE 25. REGENERATIVE MEDICINE MARKET: RESEARCHCONTACTS
  • FIGURE 26. REGENERATIVE MEDICINE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. REGENERATIVE MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL KILLER (NK) CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL KILLER (NK) CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY T CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY T CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-IMMUNE CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-IMMUNE CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STEM CELL-BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STEM CELL-BASED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY EXTRACELLULAR & ACELLULAR THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY EXTRACELLULAR & ACELLULAR THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE EDITING TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE EDITING TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RNA & DNA-BASED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RNA & DNA-BASED THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL BIOMATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL BIOMATERIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC BIOMATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC BIOMATERIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SCAFFOLDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SCAFFOLDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY XENOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY XENOGENEIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ANGIOGENESIS & VASCULAR REGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ANGIOGENESIS & VASCULAR REGENERATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONGENITAL HEART DEFECT REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONGENITAL HEART DEFECT REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MYOCARDIAL INFARCTION TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MYOCARDIAL INFARCTION TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AESTHETIC PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AESTHETIC PROCEDURES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BURN TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BURN TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CHRONIC WOUND HEALING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CHRONIC WOUND HEALING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BETA CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BETA CELL TRANSPLANTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ISLET CELL REGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ISLET CELL REGENERATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALZHEIMER'S TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALZHEIMER'S TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MULTIPLE SCLEROSIS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MULTIPLE SCLEROSIS THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PARKINSON'S THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PARKINSON'S THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SPINAL CORD INJURY REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SPINAL CORD INJURY REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STROKE RECOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STROKE RECOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TUMOR ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TUMOR ABLATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CORNEAL REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CORNEAL REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RETINAL REGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RETINAL REGENERATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BONE REGENERATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TENDON REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TENDON REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 165. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 167. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 169. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 171. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 173. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2025-2030 (USD MILLION)
  • TABLE 175. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 177. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 179. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 181. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 183. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2025-2030 (USD MILLION)
  • TABLE 185. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 187. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 189. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
  • TABLE 191. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2025-2030 (USD MILLION)
  • TABLE 193. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 195. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 215. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 217. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 235. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 239. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 241. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 243. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 245. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 246. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 247. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 248. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 249. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 250. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2025-2030 (USD MILLION)
  • TABLE 251. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 252. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 253. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 254. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 255. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 256. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 257. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 259. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2024 (USD MILLION)
  • TABLE 260. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2025-2030 (USD MILLION)
  • TABLE 261. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 263. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 265. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
  • TABLE 267. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2024 (USD MILLION)
  • TABLE 268. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2025-2030 (USD MILLION)
  • TABLE 269. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 275. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 277. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 278. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 279. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 281. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 282. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 283. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 284. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 285. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 286. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2025-2030 (USD MILLION)
  • TABLE 287. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 288. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 289. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 290. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 291. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 292. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 293. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 295. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2024 (USD MILLION)
  • TABLE 296. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2025-2030 (USD MILLION)
  • TABLE 297. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 299. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 301. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
  • TABLE 303. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2024 (USD MILLION)
  • TABLE 304. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2025-2030 (USD MILLION)
  • TABLE 305. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 307. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 310. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 311. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 313. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 314. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 315. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 317. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 319. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 320. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 321. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 322. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIA